Santhera Pharmaceuticals Holding AG (SANN.S)
23 Oct 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||Chairman of the Board|
|55||2017||Chief Executive Officer, Member of the Executive Management Board, Delegate of the Board|
|52||2017||Vice Chairman of the Board|
|58||2015||Chief Financial Officer, Member of the Executive Management Board|
|54||2015||Senior Vice President, General Counsel, Secretary to the Board, Member of the Executive Management Board|
- BRIEF-Santhera Pharma Announces Start Of Phase Ib/IIa Trial With Pol6014
- BRIEF-Santhera Pharmaceuticals: Start Of Phase Ib/IIa Trial With POL6014 In Patients With Cystic Fibrosis
- BRIEF-Santhera Gets Positive Opinion For Orphan Drug Designation In EU For Pol6014 In Cystic Fibrosis
- BRIEF-Santhera Hopes for Good News to Lift Shares, Pave Way For Capital Hike
- Swiss stocks - Factors to watch on Sept 4